0,1,2,3,4,5,6
Table 7.4:  First line immune checkpoint inhibitor combination trials for clear-cell RCC,,,,,,
Study,N,Experimental   arm,Primary   endpoint,Risk   groups,PFS (mo)  Median (95% CI)  HR,OS (mo)  Median (95% CI)  HR
"KEYNOTE-426  NCT02853331  Median   follow-up   42.8 months  [523, 524, 530]",861,PEMBRO    200 mg. IV Q3W   plus AXI 5 mg.    PO BID  vs.  SUN 50 mg    PO QD 4/2 wk,PFS and OS   in the ITT by   BICR,IMDC  FAV     31%  IMD     56%  POOR 13%  MSKCC  Not   determined,(ITT)  PEMBRO + AXI:   15.7 (13.6–20.2)  SUN: 11.1 (8.9–12.5)  HR: 0.68   (95% CI: 0.58–0.80)  p < 0.0001,(ITT)  PEMBRO + AXI:   45.7 (43.6–NR)  SUN: 40.1    (34.3–44.2)  HR: 0.73   (95% CI: 0.60–0.88)  p = 0.001
"JAVELIN 101   NCT02684006  Median   follow-up   19 months  [457, 528]",886,"AVE 10 mg/kg    IV Q2W plus    AXI, 5 mg    PO BID  vs.  SUN 50 mg    PO QD 4/2 wk",PFS in the   PD-L1+   population   and OS in   the ITT by   BICR,IMDC  FAV     22%  IMD     62%  POOR 16%  MSKCC  FAV     23%  IMD     66%  POOR 12%,(PD-L1+)  AVE + AXI:   13.8 (10.1–20.7)  SUN: 7.0 (5.7–9.6)  HR: 0.62   (95% CI: 0.49–0.78)  p < 0.0001,(PD-L1+)  AVE + AXI: NR  SUN: 28.6 (27.4–NE)  HR: 0.83   (95% CI: 0.60–1.15)  p = 0.1301
"IMmotion151  NCT02420821  Median   follow-up   24 months  [509, 529]",915,ATEZO   1200 mg fixed   dose IV plus    BEV 15 mg/kg    IV on days 1 and   22 of each 42-day   cycle  vs.  SUN 50 mg  PO QD 4/2 wk,PFS in the   PD-L1+   population   and OS in   the ITT by   IR,IMDC  Not   determined  MSKCC  FAV     20%  IMD     69%  POOR 12%,(PD-L1+)  ATEZO + BEV:   11.2 (8.9–15.0)  SUN: 7.7 (6.8–9.7)  HR: 0.74   (95% CI: 0.57–0.96)  p = 0.0217,(ITT)  ATEZO + BEV:   36.1 (31.5–42.3)  SUN: 35.3    (28.6–42.1NE)  HR: 0.91   (95% CI: 0.76–1.08)  p = 0.27
"Checkmate   214  NCT02231749  Median   follow-up of   60 months  [455, 522]",1096,NIVO 3 mg/kg   plus   IPI 1 mg/kg IV   Q3W for 4 doses   then NIVO   3 mg/kg IV Q2W  vs.  SUN 50 mg    PO QD 4/2 wk,PFS and   OS in the   IMDC inter-  mediate and   poor risk   population   by BICR,IMDC  FAV      23%  IMD      61%  POOR  17%  MSKCC  Not   determined,(IMDC IMD/poor)  NIVO + IPI:   11.6 (8.4–16.5)  SUN: 8.3 (7.0–10.4)  HR: 0.73   (95% CI: 0.61–0.87),(IMDC IMD/poor)  NIVO + IPI:   47.0 (35.4–57.4)  SUN:   26.6 (22.1–33.5)  HR: 0.68   (0.58–0.81)  p < 0.0001
"CheckMate   9ER   NCT03141177  Median   follow-up of   23.5 months  [525, 526]",651,NIVO 240 mg   fixed dose IV   every 2 wk plus   CABO 40 mg   PO daily   vs.  SUN 50 mg    PO QD 4/2 wk,PFS in the   ITT by BICR,IMDC  FAV      22%  IMD      58%  POOR  20%  MSKCC  Not   determined,(ITT)  NIVO + CABO:   17.0 (12.6–19.4)  SUN: 8.3 (6.9–9.7)  HR: 0.52   (95% CI: 0.43–0.64)  p < 0.0001,(ITT)  NIVO + CABO:    NR (NE)  SUN: 29.5 (28.4–NE)  HR: 0.66   (98.9% CI: 0.50–  0.87)  p = 0.0034
"CLEAR  NCT02811861  Median    follow-up of    33.4 months  [527, 531]",712,PEMBRO    200 mg IV Q3W   plus LEN 20 mg   PO QD  vs.  SUN 50 mg    PO QD 4/2 wk,PFS in the   ITT by BIRC,IMDC  FAV     31%  IMD     59%  POOR   9%  NE         1%  MSKCC  FAV     27%  IMD     64%  POOR   9%,(ITT)  PEMBRO + LEN:   23.9 (20.8–27.7)  SUN: 9.2 (6.0–11.0)  HR: 0.39   (95% CI: 0.32–0.49)   p > 0.001,H  (ITT)  PEMBRO + LEN:    NR (41.5–NE)  SUN: NR (38.4–E)  R: 0.72   (95% CI: 0.55–0.93)    p = 0.005
COSMIC-313  Median    follow-up of    20.2 months  [521],855,NIVO 3 mg/kg   plus IPI 1 mg/kg    IV Q3W for 4   doses then    NIVO 3 mg/kg    IV Q2W +    CABO 40 mg    PO QD  vs. NIVO 3 mg/kg    plus IPI 1 mg/kg    IV Q3W for 4   doses then    NIVO 3 mg/kg    IV Q2W,PFS in   the PITT   population   (first   550 pts.   randomised),IMDC  IMD     75%  POOR  25%,(PITT)  NIVO + IPI + CABO:   NR (14.0–NE)  NIVO + IPI:    11.3 (7.7–18.2)  HR: 0.73 (95%    CI: 0.57–0.94)    p = 0.013,NR
